Glaxo in for competition after Hikma’s generic asthma drug passes major milestone – Telegraph.co.uk


Telegraph.co.uk

Glaxo in for competition after Hikma's generic asthma drug passes major milestone
Telegraph.co.uk
Cheap versions of one of GlaxoSmithKline's top-selling asthma drugs could be available to patients as early as next year. Jordanian pharmaceuticals company Hikma moved one step closer to getting a generic version of Glaxo's Advair Diskus inhaler onto
Cipla's rival Hikma gets asthma drug nod in the USMoneycontrol.com
Vectura and Hikma's generic of Advair Diskus accepted for filing by US FDAThe Pharma Letter (registration)
Vectura Group PLC and Hikma shares given FDA boostProactive Investors UK

all 8 news articles »

View full post on asthma – Google News

iSonea reaches milestone with launch of U.S. paediatric asthma study – Proactive Investors USA & Canada


mobihealthnews

iSonea reaches milestone with launch of U.S. paediatric asthma study
Proactive Investors USA & Canada
iSonea (ASX: ISN, OTCQX: ISOAY) has begun its first large US post-market study of its WheezoMeterâ„¢ monitoring device in paediatric patients with a range of asthma symptom severity. The study will include patients who are too young to be tested with
iSonea Announces Initiation of Pediatric Asthma StudyMarketWatch (press release)
iSonea begins recruiting for pediatric asthma trialmobihealthnews
iSonea to Build Mobile Asthma Management Apps on Qualcomm's PlatformHighlight HEALTH 2.0

all 15 news articles »

View full post on asthma – Google News